A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionfbb4boorkd56jmadev028118hajij4lc): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

Saiseikai Suita Hospital[Affiliation] Publications | LitMetric

291 results match your criteria: "Saiseikai Suita Hospital[Affiliation]"

This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression treated with immune checkpoint inhibitors (ICIs) alone or combined with chemotherapy (ICI/chemotherapy). We included 411 patients with advanced NSCLC with a PD-L1 tumor proportion score of ≥50%. The patients were treated with pembrolizumab monotherapy or ICI/chemotherapy.

View Article and Find Full Text PDF

Background: Various noninvasive tests can be used to identify high-risk groups of patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD). In this study, we compared the diagnostic performance of serum type 4 collagen 7S (COL4-7S) and the Enhanced Liver Fibrosis (ELF) score for detecting fibrosis in patients with MASLD.

Methods: Among 1368 patients with MASLD who underwent liver biopsy, 794 with values for both serum COL4-7S and the ELF score were enrolled in this multicenter study.

View Article and Find Full Text PDF

Aims: Weight loss mediated by glucagon-like peptide-1 (GLP-1) analogues is lower in patients with type 2 diabetes versus those without. Type 2 diabetes and obesity are risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD) and associated steatohepatitis (MASH). We evaluated weight changes in adults with MASLD/MASH with or without type 2 diabetes receiving the GLP-1 analogue semaglutide.

View Article and Find Full Text PDF
Article Synopsis
  • - MASLD, previously known as NAFLD, can affect people with normal body weight, splitting into two categories: lean MASLD (with cardiometabolic risk factors) and cryptogenic steatotic liver disease (without these factors).
  • - Research shows that the PNPLA3 rs738409 genetic variant is more prevalent in individuals with lean NAFLD compared to those who are overweight or obese, but cardiometabolic risk factors usually still play a role in liver issues.
  • - Although the PNPLA3 gene is linked to severe liver conditions and complications, its specific effects on lean individuals with NAFLD have not been thoroughly investigated.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the role of thyroid transcription factor 1 (TTF-1) as a predictor for treatment response in advanced non-squamous non-small-cell lung cancer (NSCLC) patients undergoing chemotherapy or chemoimmunotherapy with specific levels of PD-L1 expression.
  • Out of 624 patients surveyed, 283 met the criteria, revealing that TTF-1 positivity was associated with significantly longer progression-free survival (PFS) and overall survival (OS) in those receiving chemotherapy, but not in the chemoimmunotherapy group.
  • The findings suggest that TTF-1 expression can help predict treatment effectiveness for chemotherapy, while its impact on chemoimmunotherapy remains unclear in patients with PD-L1 levels between
View Article and Find Full Text PDF

Objective: To evaluate comorbidities in Japanese testicular cancer (TC) survivors in a multi-institutional, cross-sectional study.

Methods: This study enrolled TC survivors who visited any of the eight high-volume institutions in Japan from 2018 to 2019. After obtaining informed consent, participants answered questionnaires about their comorbidities.

View Article and Find Full Text PDF
Article Synopsis
  • Fibro-Scope is an AI system designed for noninvasive diagnosis of liver fibrosis in patients suffering from metabolic dysfunction-associated steatotic liver disease, and the study assessed its effectiveness alongside the FIB-4 index in a cohort of Japanese patients.
  • A 6.4-year study involving 796 patients showed that the combined method classified patients into low, high, and middle-risk groups, achieving 84% sensitivity and specificity for detecting advanced fibrosis.
  • The two-step method proved valuable in identifying high-risk individuals, supporting its use as a cost-effective and practical screening tool in clinical settings in Japan.
View Article and Find Full Text PDF

Hepatocyte-specific GDF15 overexpression improves high-fat diet-induced obesity and hepatic steatosis in mice via hepatic FGF21 induction.

Sci Rep

October 2024

Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyou-ku, Kyoto, 602-8566, Japan.

Article Synopsis
  • GDF15 and FGF21 are liver-secreted cytokines that show potential as treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), but their interaction is not fully understood.
  • Overexpressing GDF15 or FGF21 in mice on a high-fat diet led to reduced body weight, fat mass, and insulin resistance, with GDF15 also lowering weight without affecting food intake.
  • GDF15 may enhance fatty acid metabolism and induce FGF21 expression through specific cellular mechanisms, indicating that their interaction is significant for addressing MASLD.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to improve the prediction of liver-related events (LRE) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) by combining the Fibrosis-4 (FIB-4) index with genetic polymorphism data.
  • Researchers enrolled 1,304 Japanese patients, identifying key genotypes associated with LRE while tracking outcomes over an 8.1-year follow-up period, during which 96 LREs occurred.
  • The findings suggested that a two-step screening strategy using the FIB-4 index followed by genetic assessment effectively identifies high-risk patients, with notable differences in survival rates and LRE development across risk groups.
View Article and Find Full Text PDF

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study.

Clin Gastroenterol Hepatol

October 2024

MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang, China. Electronic address:

Article Synopsis
  • Scientists studied a health problem called MASH, which affects people's livers, and worked on two tests to help doctors tell if someone has it.
  • They looked at data from over 3,000 people to make sure their first test, called acMASH, worked well, and then created a new test called acFibroMASH to find more severe cases.
  • The new acFibroMASH test was better at predicting who might have future liver problems compared to another test, showing it's a useful tool for doctors to keep patients healthy.
View Article and Find Full Text PDF

Aim: Nocturia impairs the quality of life in patients with type 2 diabetes mellitus. Although sodium glucose co-transporter 2 inhibitors (SGLT2i) such as tofogliflozin increase urine volume, their impact on nocturia, in conjunction with dietary salt restriction, is less clear.

Materials And Methods: This multicenter, open-label, randomized, parallel-group trial included 80 subjects with type 2 diabetes and nocturia.

View Article and Find Full Text PDF

Background: Tumor markers such as serum carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) are utilized for assessing the effectiveness of chemotherapy in non-small cell lung cancer (NSCLC) patients. Yet, it remains uncertain whether these markers can reliably forecast responses to combined chemoimmunotherapy. Our study aimed to examine the significance and effectiveness of these markers in predicting responses among NSCLC patients undergoing combined chemoimmunotherapy.

View Article and Find Full Text PDF

The association between depth of response (DpR) and treatment outcomes has been documented across various types of cancer. Immune checkpoint inhibitor (ICI)-based treatment is globally used as first-line treatment for non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression ≥ 50%. However, in this population, the significance of DpR is not elucidated.

View Article and Find Full Text PDF

Because hepatic stellate cells (HSCs) play a major role in fibrosis, we focused on HSCs as a potential target for the treatment of liver fibrosis. In this study, we attempted to identify drug candidates to inactivate HSCs and found that several proteasome inhibitors (PIs) reduced HSC viability. Our data showed that a second-generation PI, carfilzomib (CZM), suppressed the expression of fibrotic markers in primary murine HSCs at low concentrations of 5 or 10 nM.

View Article and Find Full Text PDF

Background: The optimal subsequent treatment strategy for locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy (CRT) and consolidative durvalumab therapy remains unknown. We aimed to determine the optimal subsequent treatment strategy for this clinical population.

Materials And Methods: We retrospectively enrolled 523 consecutive patients with LA-NSCLC treated with CRT and analyzed the treatment outcomes of subsequent therapy after progression following CRT and consolidative durvalumab therapy.

View Article and Find Full Text PDF
Article Synopsis
  • Nonalcoholic fatty liver diseases (NAFLD) and nonalcoholic steatohepatitis (NASH) can lead to hepatocellular carcinoma (HCC), prompting a study of risk stratification methods using histological features and noninvasive markers in patients with liver biopsy-confirmed NAFLD or NASH.
  • The study included 1389 patients and compared the predictive ability of histological factors and noninvasive models such as the aMAP score, FIB-4 index, and ALBI score, revealing that the aMAP score had the highest predictive power for HCC.
  • The aMAP score and FIB-4 index were found to be superior to histological features for
View Article and Find Full Text PDF

High Plasma D-Dimer Levels Correlate with Ictal Infarction and Poor Outcomes in Spontaneous Subarachnoid Hemorrhage.

World Neurosurg

October 2024

Department of Neurosurgery, Osaka Mishima Emergency Critical Care Center, Takatsuki, Japan; Department of Anesthesiology, Osaka Saiseikai Suita Hospital, Suita, Japan.

Background: Early brain injury is the leading cause of poor outcomes in spontaneous subarachnoid hemorrhage (sSAH). Plasma D-dimer levels and acute cerebral ischemia have been highlighted as relevant findings in early brain injury; however, their correlation has not been substantially investigated.

Methods: This retrospective, single-center cohort study was conducted at a tertiary emergency medical center from January 2004 to June 2022.

View Article and Find Full Text PDF

Introduction: Several studies explored the association between thyroid transcription factor-1 (TTF-1) and the therapeutic efficacy of immunotherapy. However, the effect of TTF-1 on the therapeutic efficacy of programmed death-1 (PD-1) inhibitor/chemoimmunotherapy in patients with non-squamous non-small cell lung cancer (non-Sq NSCLC) with a programmed death-ligand 1 (PD-L1) tumor proportion score of 50% or more who are highly susceptible to immunotherapy remains unresolved. Therefore, we evaluated whether TTF-1 has a clinical impact on this population.

View Article and Find Full Text PDF

Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11.

Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members.

View Article and Find Full Text PDF

Background And Aims: This study aimed to determine the safety and efficacy of atezolizumab + bevacizumab therapy in hepatocellular carcinoma patients receiving anti-platelet agents or anticoagulants.

Methods: Patients were divided into those using (IM out) and those not using (IM in) anti-platelet agents or anticoagulants, who violated the exclusion criteria of the IMbrave150 trial, and were retrospectively examined.

Results: The study included 185 patients (IM in: 157; IM out: 28).

View Article and Find Full Text PDF
Article Synopsis
  • * The study involved 639 patients who did not develop HCC for over 7 years and 46 who did within that time; the model achieved an accuracy of 81.0% and showed effective validation results.
  • * The deep learning model could detect early signs of HCC even in patients with mild fibrosis by analyzing key pathological features, suggesting its potential for improving early diagnosis.
View Article and Find Full Text PDF

Treatment strategies for patients with out-of-hospital cardiac arrest associated with traumatic brain injury: A case series.

Am J Emerg Med

August 2024

Osaka Mishima Emergency Critical Center, 11-1 Minami-akutagawacho, Takatsuki, Osaka 569-1124, Japan; Department of Neurosurgery, Japanese Red Cross Kitami Hospital, 2-1 Kita 6-jo, higashi, Kitami, Hokkaido 090-8666, Japan. Electronic address:

Introduction: Collapse after out-of-hospital cardiac arrest (OHCA) can cause severe traumatic brain injury (TBI). We aimed to investigate the clinical characteristics and treatment strategies for patients with OHCA and TBI.

Methods: We analyzed a consecutive cohort of patients with intrinsic OHCA retrospectively treated between January 2011 and December 2021 at a single critical care center, and presented a case series of seven patients.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers found that the Fibrosis-3 (FIB-3) index can accurately predict liver fibrosis progression in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), regardless of age.
  • In a study of 1,398 patients, the FIB-3 index performed as well as the Fibrosis-4 (FIB-4) index for those under 60, but outperformed it for patients aged 60 and older.
  • The FIB-3 index’s effectiveness suggests it could be a more reliable tool for assessing liver fibrosis than existing methods, enhancing diagnosis across different age groups.
View Article and Find Full Text PDF

Aims: A multi-stakeholder consensus has proposed MASLD (metabolic dysfunction-associated steatotic liver disease). We aimed to investigate the pathological findings related to the mid-term mortality of patients with biopsy-proven MASLD in Japan.

Methods: We enrolled 1349 patients with biopsy-proven MASLD.

View Article and Find Full Text PDF